Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020109806 - UTILISATION DE CANNABINOÏDES DANS LE TRAITEMENT DE L'ÉPILEPSIE


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/GB2019/053372 P267157WOAWE
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
28 November 2019 30 November 2018
Applicant
GW RESEARCH LIMITED
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 31/05 (2006.01)i; A61K 36/00 (2006.01)i; C07K 14/705 (2006.01)i; A61P 25/08 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K; C07K; A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
Y
GB 2531282 A (GW PHARMA LTD [GB]) 20 April 2016 (2016-04-20)
1-11
the whole document
paragraph [0047]
example 1
claims 1-12
(2)
Y
US 2015359755 A1 (GUY GEOFFREY [GB] ET AL) 17 December 2015 (2015-12-17)
1-11
the whole document
paragraph [0046]
examples 2,4
claims 1-24
(3)
Y
GB 2531278 A (GW PHARMA LTD [GB]) 20 April 2016 (2016-04-20)
1-11
the whole document
paragraph [0042]
example 1
claims 1-13
(4)
Y
GB 2531280 A (GW PHARMA LTD [GB]) 20 April 2016 (2016-04-20)
1-11
the whole document
paragraph [0045]
example 1
claims 1-14
(5)
Y
STOCKINGS E. ET AL, "Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY,Vol. 89, No. 7, 06 March 2018 (2018-03-06), page 741-753,
XP055657257
1-11
the whole document
(6)
Y
GOLYALA A. ET AL, "Drug development for refractory epilepsy: The past 25 years and beyond", SEIZURE,Vol. 44, 06 December 2016 (2016-12-06), page 147-156,
XP029901803
1-11
the whole document
page 152, right-hand column, lines 24-39
(7)
Y
HAUSMAN-KEDEM M. ET AL, "Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study", BRAIN AND DEVELOPMENT,Vol. 40, No. 7, 01 August 2018 (2018-08-01), page 544-551,
XP055660691
1-11
the whole document
(8)
Y
ROSENBERG E. C. ET AL, "Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol", EPILEPSIA,Vol. 58, No. 8, 15 June 2017 (2017-06-15), page e96-e100,
XP055657251
1-11
the whole document
(9)
Y
DEVINSKY O. ET AL, "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome", THE NEW ENGLAND JOURNAL OF MEDICINE,Vol. 376, No. 21, 25 May 2017 (2017-05-25), page 2011-2020,
XP055581640
1-11
the whole document
(10)
Y
PRESS C. A. ET AL, "Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy", EPILEPSY & BEHAVIOR,Vol. 45, 03 April 2015 (2015-04-03), page 49-52,
XP055205370
1-11
cited in the application
the whole document
(11)
Y
PORTER B. E. ET AL, "Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy", 01 December 2013 (2013-12-01), Vol. 29, No. 3, page 574-577,
XP028775189
[retrieved on  2013-11-15]
1-11
cited in the application
the whole document
(12)
Y
VEZYROGLOU K. ET AL, "Targeted Treatment in Childhood Epilepsy Syndromes", 07 May 2016 (2016-05-07), Vol. 18, No. 6, page 1-12,
XP035950701
[retrieved on  2016-05-07]
1-11
the whole document
Cannabidiol (CBD);page 7 - page 8
Memantine in GRIN2A-related epileptics;page 9
(13)
Y
MAO K. ET AL, "High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect", INT J CLIN EXP MED,Vol. 8, No. 6, 15 June 2015 (2015-06-15), page 8820-8827,
XP055660655
1-11
the whole document
(14)
Y
RODRÍGUEZ-MUÑOZ M. ET AL, "Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor", MOLECULAR BRAIN,Vol. 11, No. 1, 17 September 2018 (2018-09-17), page 1-12,
XP055660650
1-11
the whole document
(15)
A
WEI F. ET AL, "Ion Channel Genes and Epilepsy: Functional Alteration, Pathogenic Potential, and Mechanism of Epilepsy", 09 May 2017 (2017-05-09), Vol. 33, No. 4, page 455-477,
XP036283175
[retrieved on  2017-05-09]
1,11
the whole document
N-Methyl-D-Aspartate Receptor (NMDAR) Genes;page 465 - page 467
(16)
A
ADDIS L. ET AL, "Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue", SCIENTIFIC REPORTS,Vol. 7, No. 1, 27 February 2017 (2017-02-27),
XP055559141
1,11
the whole document
(17)
T
PERUCCA P. ET AL, "Identifying mutations in epilepsy genes: Impact on treatment selection", EPILEPSY RESEARCH.,Vol. 152, 04 March 2019 (2019-03-04), page 18-30,
XP055660798
1,11
the whole document
4. Epilepsies due to mutations in N-methyl-D-aspartate (NMDA) receptor genes
(18)
T
AGUILAR-CASTILLO M J ET AL, "Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene", CLINICA CHIMICA ACTA,Vol. 493, 01 June 2019 (2019-06-01), page S604-S618,
XP055661121
1,11
abstract W352
(19)
A,P
WO 2019071302 A1 (UNIV SYDNEY [AU]) 18 April 2019 (2019-04-18)
1-11
the whole document
page 15, lines 4-12
figure 2
example 1
(20)
A,P
WO 2019045121 A1 (TAKEDA PHARMACEUTICALS CO [JP]) 07 March 2019 (2019-03-07)
1-11
the whole document
paragraphs [0021], [0022], [0027]
claims 2,3,23,25
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
GB 2531282 A
20 April 2016
AU 2015332212 A1
BR 112017007777 A2
CA 2963208 A1
EP 3206716 A1
GB 2531282 A
JP 2017531667 A
US 2016166515 A1
US 2017172941 A1
US 2017266126 A1
US 2019091171 A1
US 2020000741 A1
WO 2016059403 A1
20 April 2017
16 January 2018
21 April 2016
23 August 2017
20 April 2016
26 October 2017
16 June 2016
22 June 2017
21 September 2017
28 March 2019
02 January 2020
21 April 2016
US 2015359755 A1
17 December 2015
AU 2015275886 A1
AU 2015275887 A1
BR 112016029498 A2
BR 112016029506 A2
CA 2952858 A1
CA 2952994 A1
EP 3157511 A1
EP 3157512 A1
ES 2680656 T3
ES 2680679 T3
GB 2530001 A
GB 2531093 A
JP 2017519758 A
JP 2017524672 A
PL 3157511 T3
PL 3157512 T3
US 2015359755 A1
US 2015359756 A1
US 2017172939 A1
US 2017172940 A1
US 2017173043 A1
US 2017173044 A1
US 2017181982 A1
US 2017246121 A1
US 2018338931 A1
WO 2015193667 A1
WO 2015193668 A1
12 January 2017
12 January 2017
22 August 2017
22 August 2017
23 December 2015
23 December 2015
26 April 2017
26 April 2017
10 September 2018
10 September 2018
16 March 2016
13 April 2016
20 July 2017
31 August 2017
28 February 2019
28 February 2019
17 December 2015
17 December 2015
22 June 2017
22 June 2017
22 June 2017
22 June 2017
29 June 2017
31 August 2017
29 November 2018
23 December 2015
23 December 2015
GB 2531278 A
20 April 2016
EP 3206679 A1
GB 2531278 A
US 2017231923 A1
WO 2016059404 A1
23 August 2017
20 April 2016
17 August 2017
21 April 2016
GB 2531280 A
20 April 2016
EP 3206680 A1
GB 2531280 A
US 2017239193 A1
WO 2016059405 A1
23 August 2017
20 April 2016
24 August 2017
21 April 2016
WO 2019071302 A1
18 April 2019
NONE
WO 2019045121 A1
07 March 2019
NONE
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
23 January 2020
Date of mailing of the international search report:
30 January 2020
Authorized officer:
van de Kamp, Mart
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E